Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Recs

1
Player Avatar Igasu (< 20) Submitted: 12/28/2012 6:02:09 PM : Outperform Start Price: $1.81 NVAX Score: +89.19

NVAX has new homogenate to make its patented Viral Like Particles that uses insect homogenate v eggs. (Currently takes about a billion eggs/yr to make our flu vaccine) Factories are much cheaper to build. The hysteresis from virus to vaccine is half the time of conventional vaccines. They have an RSV vaccine that appears to be very immunogenic. (The only one out there right now)

Featured Broker Partners


Advertisement